e-learning
resources
Munich 2006
Tuesday 05.09.2006
Epidemiology, clinical features, malignant pleural diseases, treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma
G. Kirbas, A. Abakay, A. Senyigit, O. Abakay (Diyarbakir, Turkey)
Source:
Annual Congress 2006 - Epidemiology, clinical features, malignant pleural diseases, treatment
Session:
Epidemiology, clinical features, malignant pleural diseases, treatment
Session type:
Poster Discussion
Number:
4492
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Kirbas, A. Abakay, A. Senyigit, O. Abakay (Diyarbakir, Turkey). Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma. Eur Respir J 2006; 28: Suppl. 50, 4492
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Post partum
dyspnoea: look beyond the lungs
Related content which might interest you:
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Prognostic characteristics of malignant pleural mesothelioma
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM)
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Prognostic factors in diffuse malignant pleural mesothelioma
Source: Eur Respir J 2003; 22: Suppl. 45, 62s
Year: 2003
Prognostic factors in diffuse malignant pleural mesothelioma
Source: Eur Respir J 2007; 30: Suppl. 51, 755s
Year: 2007
Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients
Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines
Year: 2009
The analysis of clinicopathological characteristics and prognosis of malignant pleural mesothelioma
Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases
Year: 2013
Diagnostic and prognostic significance of survivin levels in malignant pleural effusion
Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Year: 2011
Prognostic significance of neutrophil predominance in pleural fluid in patients with malignant effusion
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM)
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Therapeutic outcome and prognostic factors in patients with pleural mesothelioma
Source: Eur Respir J 2005; 26: Suppl. 49, 73s
Year: 2005
Prognostic impact of histology and treatment modalities in malignant mesothelioma
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013
Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
Malignant pleural mesothelioma clinical aspects and survival in 93 cases
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
Prognostic factors in patients with malignant pleural effusion undergoing thoracoscopy
Source: Annual Congress 2011 - From outside to inside: access to the pleura
Year: 2011
Pathological diagnosis of malignant pleural mesothelioma
Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases
Year: 2020
Diagnostic utility of biochemical parameters in patients with pleural effusions
Source: Eur Respir J 2001; 18: Suppl. 33, 386s
Year: 2001
Prognostic value of metabolic imaging in non small cell lung cancers with neoplasic pleural effusion
Source: Eur Respir J 2007; 30: Suppl. 51, 206s
Year: 2007
Clinical and laboratorial variables useful in the differential diagnosis of pleural effusions secondary to tuberculosis or lymphoma
Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept